Back

Use of incretin-based therapies.

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease? Metabolic Syndrome, Insulin, Insulin Resistance ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

3 More presentations in this session

Presentation thumbnail
Epigenetic signatures and cardiovascular risk in diabetes.
Professor F. Cosentino (Stockholm, SE)
Presentation thumbnail
Mechanisms of cardiovascular impact of SGLT2 inhibitors.
Professor B. Staels (Lille Cedex, FR)
Slides Video
Presentation thumbnail
SGLT2 inhibitors and alteration of substrate metabolism.
Professor E. Ferrannini (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources